Status:
COMPLETED
Expressive Storytelling to Share Adolescents/Young Adults Cancer Stories
Lead Sponsor:
Vanderbilt University
Collaborating Sponsors:
Vanderbilt University Medical Center
Conditions:
Pediatric Cancer
Growth, Posttraumatic
Eligibility:
All Genders
15-25 years
Phase:
NA
Brief Summary
The purpose of this study is to test the feasibility, acceptability, and preliminary efficacy of an online expressive storytelling intervention for adolescents and young adults (AYA) with cancer. * S...
Detailed Description
* Rationale/Significance of Study: Cancer is one of life's most stressful and serious illnesses for adolescents and young adults (AYA). In 2021, approximately 15,000 AYA ages 15 to 25 years are expect...
Eligibility Criteria
Inclusion
- \[Inclusion Criteria\] 1.1 AYA ages 15 to 25 years. Age criterion was determined based on (a) the age criteria of adolescence (15-17 years) and emerging adulthood (18-25 years) guided by lifespan developmental frameworks35 and (b) the intervention being developmentally appropriate for this unique age group.
- 2 Patients must have any type of histologically or cytologically confirmed malignancy during adolescence or young adulthood.
- 3 Patients may be at any stage of the cancer trajectory. Participants can be enrolled beginning one month after an initial cancer diagnosis.
- 4 Patients must be cognitively intact.
- 5 Patients must have access to the internet using their own electronic devices (e.g., laptop, desktop, tablet PC, smartphone).
- 6 Ability to speak, write, read, understand English.
- \[Exclusion Criteria\] 2.1 Patients who have any unanticipated needs that cannot be accommodate by the PI (e.g., technical challenges, permanent loss of electronic devices, permanently unable to access the internet) can be excluded before and during the participation.
- 2 Patients who show their unwillingness to participate in the program by their actions (e.g., providing false information, just giggling rather than answering questions, increases in aggression or anxiety) can be discussed to make a decision about honoring their desire to withdraw from participation.
Exclusion
Key Trial Info
Start Date :
November 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04855487
Start Date
November 10 2021
End Date
May 1 2022
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232